Prevalence of Transmissible Infections Among Breast Cancer Patients in Calabar, Nigeria

Download PDF - 384 Downloads

 
 

Joseph E. Udosen, Euphoria C. Akwiwu, Utibe-Abasi Felix, David U. Akpotuzor, Josephine O. Akpotuzor

AJLHTS: Original Paper

Abstract 

Introduction: Transmissible infections including those of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis remain public health challenges. The co-existence of these infections with other disease conditions of medical importance can be quite challenging, particularly if there is no prior knowledge of the infection status. Apart from the direct impact on the affected patient, there is also the concern of safety for care givers as well as the risk of nosocomial transmission to other patients. This study focused on pre- operative screening of breast cancer patients to determine the prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis infections

Materials and Methods: This study was conducted among breast cancer patients in Calabar, Cross River State of Nigeria. A structured questionnaire was administered by two trained interviewers to obtain biodata and socio-demographic characteristics. Screening for antibodies to HIV, HBV, HCV and Syphilis were performed by standard serological techniques

Results: General prevalence for all the screened infections was 18%. Distribution of specific infections revealed hepatitis B viral infection to be highest (8%), followed by HIV infection (6%). Hepatitis C virus infection and syphilis were the least with 2% rates each. Among participants living with these infections, 33% had previous knowledge of their status, while the remaining 67% had no prior knowledge. 

Conclusion: Hepatitis B virus had the highest prevalence while the lowest were HCV and syphilis. Greater percentage of infected subjects were not aware of their status prior to the preoperative screening

Key words: Breast cancer, transmissible infections, prevalence

Download PDF - 384 Downloads

 
 

Proportions of Blood Cell Deficits in Breast Cancer Patients Undergoing Chemotherapy

Download PDF - 396 Downloads

 
 

Joseph E. Udosen, Euphoria C. Akwiwu, Valerie E. Njar, David U. Akpotuzor, Josephine O. Akpotuzor

AJLHTS: Original Paper

Abstract 

Introduction: Anaemia, leucopenia and thrombocytopenia are at the forefront of haematological derangements encountered in the management of breast cancer. However, there is a gap in knowledge regarding their degree of occurrence at different stages of chemotherapy

Methods: Longitudinal design and purposive sampling technique were adopted to enroll 50 adult female breast cancer patients who were accessing chemotherapy at the University of Calabar Teaching Hospital in Calabar, Cross River State of Nigeria. Ethical approval and informed consent were duly obtained. The blood cell counts were carried out by automation. Frequencies of anaemia, leucopenia and thrombocytopenia were calculated after applying cut-off point using age- and genderspecific refence ranges (<120 g/l of Haemoglobin concentration for anaemia, <4.0 x 109/1 of total white blood cell count for leucopenia and <150 x 10‘/1 of platelet count for thrombocytopenia)

Results: A greater number of the subjects had anaemia with prevalence ranging from 78% at the onset to 100% by the fifth course. Leucopenia ranged from 14% at the beginning to 100% by the third course. Thrombocytopenia was not present at pre-chemotherapy stage but appeared slightly (4%) during the assessment for second treatment course and rose to 55% at the last assessment. 

Conclusion: This study observed increasing proportions of cytopenia in association with progressing chemotherapy. There is high prevalence of anaemia in breast cancer even before commencement of chemotherapy, while leucopenia develops more rapidly during chemotherapy.

Download PDF - 396 Downloads

 
 

Platelet indices as useful biomarkers in SARS-CoV-2 infection

Download PDF - 363 Downloads

 
 

Obebinaru Constable, Theresa Awortu Jeremiah and Zaccheaus Awortu Jeremiah

AJLHTS: Original Paper

 

Abstract 

Introduction: The indices of platelets are biomarkers of platelet activation and could be useful for diagnosis and management of COVID-19 infection. This study was aimed at evaluating the impact of COVID-19 infection on some platelet indices in Port Harcourt

Materials and Methods: The study population consisted of twenty- two (22) COVID-19 positive and fifty (50) COVID-19 negative (controls). Their ages range from 20-65 years old. Five milliliters of venous blood was collected into EDTA anticoagulant bottles for platelet indices determination using an auto analyzer (Sysmex XP- 300), while naso pharyngeal swab was collected for confirmation of COVID-19 by RT-PCR molecular method

Results: The overall prevalence of COVID-19 in this study population was 30.56%. Chi square analysis revealed that this prevalence rate is very significant. (x=10.889; P=0.001). The mean PDW values of COVID-19 positive subjects (16.24±0.08fl) was significantly increased when compared with the value of the negative subjects (15.93±0.10fl) (t=2.441, P< 0.01). There was no statistically significant difference in the platelet count when the two groups were compared. However, the platelet count of the positive female COVID-19 subjects (216.27±19.65×10’/L) was significantly reduced when compared with their male counterparts (247.36±19.65×10‘/L). The reverse is the case in the negative (control) group (F=4.6825, p<0.03). There was a significant negative correlation between MPV and platelets (r= -0.489, p< 0.003). The platelet count of COVID-19 positive subjects was reduced even though not statistically significant

Conclusion: Platelet indices such as PDW and MPV could serve as surrogate biomarkers in SARS-CoV-2 infection

Download PDF - 363 Downloads

 
 

Instructions For Authors

Thank you for your interest in African Journal of Laboratory Haematology and Transfusion Science (AJLHTS). Authors should kindly note that submission implies that the content of the manuscript has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. 

Submitted manuscript for publication should be presented as follows: 

Your manuscript: this can be a single file including text, figures, and tables. All required sections should be contained in your

manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. References should be in American Medical Association Manual (AMA) of Style 10th Edition format and numbered consecutively in order of appearance and should be consistent throughout the manuscript. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers. The editorial office may send manuscript back to you for revision if your manuscript is difficult to read. 

The title page of the manuscript, including names of authors, affiliation(s), emails, statements relating to our ethics and integrity policies. 

Manuscripts should be submitted online at www.hbtssn.org/ajlhts or to the email: editorialassistant.ajlhts@hbtssn.org

Instructions For Authors PDF - 633 Downloads

 
 

INSTRUCTION FOR AUTHORS

Download PDF - 367 Downloads

 
 

Thank you for your interest in African Journal of Laboratory Haematology and Transfusion Science (AJLHTS). Authors should kindly note that submission implies that the content of the manuscript has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. 

Submitted manuscript for publication should be presented as follows

Your manuscript: this can be a single file including text, figures, and tables. All required sections should be contained in your manuscript, including abstract, introduction,

Download PDF - 367 Downloads

 
 

APPRECIATION

 

The AJLHTS Editorial Board sincerely appreciates all the manuscript reviewers for Volume 1(issue 1,2,3 and 4) 2022 

Prof Olutayo I. Ajayi University of Benin, Nigeria

Prof Josephine Akpotuzor – University of Calabar, Nigeria

Dr Nancy Ibeh – Nnamdi Azikiwe University, Awka, Nigeria

Dr Eze, Evelyn Mgbeoma – Rivers State University, Port Harcourt, Nigeria

Dr Ben Eledo – Federal Medical Centre, Bayelsa, Nigeria

Dr Alhaji Bukar – University of Maiduguri, Nigeria

Dr Marcus Chilaka – University of Bradford, United Kingdom

Prof. M. A. Muhibi – Edo State University, Uzairue, Nigeria

Prof. Z.A. Jeremiah – Rivers State University, Port Harcourt, Nigeria

Dr Rose Amaechi – Ambrose Ali University, Ekpoma, Nigeria

Dr Okezie Okamgba – Abia State University, Uturu, Nigeria

Dr Solomon Umukoro – Medical Research Council, The Gambia, West Africa

 

Challenges of bone marrow transplant for sickle cell disease in resource limited setting

Download PDF - 365 Downloads

 
 

Chisara Sylvestina Okolo and Ayodeji Olusola Dickson Olayanju

AJLHTS: Original Paper

 

Summary 

Sickle cell disorders (SCD) are a group of inherited disorders that results from both parent being carriers, haemoglobin AS resulting in haemoglobin (SS), causing anemia, infections, pain, stroke, priapism, sequenstration crisis, multiple organ dysfunctions etc. There are several ways of managing sickle cell disorder but the best way, which is considered a gold standard cure for the disease is a successful bone marrow transplant of haematopoietic stem cells (HSCT). Bone marrow (BM), Peripheral blood (PBSC) and Umbilical cord blood (UCB) are rich in stem cells. In order to have a good bone marrow transplant, without graft rejection, the laboratory plays a vital role especially in compatibility testing of donor and recipients at the various stages of the transplant, which includes initial stage, during the transplant and follow up testing to ensure tolerance to the new graft and testing for chimerism. There are various types of transplant which include Autologous, Allogeneic (Sibling/Unrelated Donor), Parent or relative, etc. The various pre transplant tests includes: Sickling test, High Performance Liquid Chromatograph (HPLC), Genetic studies, RBC Indices Hb 6-9 gm/dL, Peripheral Smear, Retic count Reticulocytosis, ESR, Bone marrow analysis. Post-transplant test Includes Engraftment Analysis, Complete Blood counts, kidney function, liver function, Cholesterol, HIV, Hepatitis B, Hepatitis C, additional infectious studies (Endemic testing), Urinalysis etc. Haemopoietic transplantation challenges in a resource limited settings like Nigeria are enormous and they includes: Danger of serious illness associated with donor-to-patient stem cell transplant, lack of appropriate donors, Graft-versus-host disease (GVHD), Inadequate Human resource, Inadequate equipped facility, cost of the service, Corruption, Lack of political will, Leadership incompétence,

Chisara Sylvestina Okolo,Ayodeji Olusola Dickson Olayanju 

strategic planing, Policy inconsistency, Lack of qualified personnel, Poor healthcare administration, Conflict of interest among health workers. The cost of Bone Marrow Transplantation is highly exorbitant to Nigerians and government need to play vital role towards funding part of the cost and alleviating the pain of sickle cell. Effective implementation of National Health Insurance Scheme and address corruption are the most efficient ways the cost would be subsidized. Appropriate information campaigns largely championed by maternal and child healthcare professionals would significantly contribute to raising the level of awareness and acceptance of Cord Blood donation. Training and re training of medical personnel cannot be over emphasized.

Download PDF - 365 Downloads

 
 

Some haematological parameters of welders exposed to oxyacetylene in Calabar, Nigeria.

Download PDF - 383 Downloads

 
 

Joyce Ezekiel Etura, Kenneth Igbor Ebi, Uwem Okon Akpan, Enosakhare Aiyudubie Asemota and Anthony Ogbonnaya Emeribe

AJLHTS: Original Paper

Abstract 

Introduction: Polymorphonuclear neutrophils (PMN) are the only leucocytes that are competent to produce large amounts of reactive oxygen species (ROS) to kill phagocytized bacteria. In leukaemia, we hypothesized this bactericidal function might be hampered. The goal of this study was to assess respiratory burst activity of PMN in leukaemia compared with non-leukaemic control subjects. We assessed the respiratory burst function of PMN as an effective defence against pathogens in leukaemia and control subjects

Materials and Methods: Peripheral blood samples were collected from leukaemia and control subjects (30 in each case) in lithium heparin anticoagulant containers. Our study cases were 30 leukaemia belonging to different subtypes (AML=12, CML=12, ALL=4 and CLL=2), 22 males and 8 females age range from 2.5-63 years (M±SEM, 28.0±3.4 years); the controls were 26 males and 4 females, age range from 17-53 years (M±SEM, 31.1±1.5 years), respectively. The respiratory burst activity was assessed using the nitroblue tetrazolium (NBT) dye reduction test on stimulated and un-stimulated PMN in leukaemia and control groups

Results: The cells purity in leukaemia was >99% using Turk’s solution and cells viability was >95% by Trypan blue dye exclusion test. The respiratory burst activity of PMNs showed a statistically significant increase (P<0.05) in controls compared with leukaemia subtypes. Similarly, comparison within leukaemia subtypes indicates

statistically significant increase (P<0.05) RBA in CML compared with AML, ALL and CLL, respectively

Conclusion: The respiratory burst activity of PMNs in leukaemia is variable with enhanced activity in CML subjects, while depressed in AML, ALL and CLL subtypes; suggesting impaired bactericidal capacities of PMNs in these diseases.

Download PDF - 383 Downloads